全文获取类型
收费全文 | 60910篇 |
免费 | 3831篇 |
国内免费 | 286篇 |
专业分类
耳鼻咽喉 | 823篇 |
儿科学 | 1537篇 |
妇产科学 | 937篇 |
基础医学 | 7175篇 |
口腔科学 | 1347篇 |
临床医学 | 6326篇 |
内科学 | 12698篇 |
皮肤病学 | 1097篇 |
神经病学 | 6056篇 |
特种医学 | 2111篇 |
外科学 | 10197篇 |
综合类 | 662篇 |
一般理论 | 70篇 |
预防医学 | 4421篇 |
眼科学 | 1278篇 |
药学 | 3676篇 |
2篇 | |
中国医学 | 59篇 |
肿瘤学 | 4555篇 |
出版年
2023年 | 258篇 |
2022年 | 203篇 |
2021年 | 1053篇 |
2020年 | 696篇 |
2019年 | 1196篇 |
2018年 | 1436篇 |
2017年 | 1093篇 |
2016年 | 1241篇 |
2015年 | 1402篇 |
2014年 | 1996篇 |
2013年 | 2804篇 |
2012年 | 4381篇 |
2011年 | 4806篇 |
2010年 | 2639篇 |
2009年 | 2466篇 |
2008年 | 4231篇 |
2007年 | 4410篇 |
2006年 | 4336篇 |
2005年 | 4351篇 |
2004年 | 4087篇 |
2003年 | 3899篇 |
2002年 | 3621篇 |
2001年 | 444篇 |
2000年 | 375篇 |
1999年 | 525篇 |
1998年 | 698篇 |
1997年 | 579篇 |
1996年 | 499篇 |
1995年 | 546篇 |
1994年 | 455篇 |
1993年 | 397篇 |
1992年 | 299篇 |
1991年 | 260篇 |
1990年 | 237篇 |
1989年 | 207篇 |
1988年 | 250篇 |
1987年 | 200篇 |
1986年 | 195篇 |
1985年 | 204篇 |
1984年 | 221篇 |
1983年 | 241篇 |
1982年 | 332篇 |
1981年 | 296篇 |
1980年 | 231篇 |
1979年 | 96篇 |
1978年 | 136篇 |
1977年 | 118篇 |
1976年 | 78篇 |
1975年 | 59篇 |
1973年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Cynthia S. E. Hendrikse MD Phyllis van der Ploeg MD PhD Nienke M. A. van de Kruis MD Jody H. C. Wilting MD Floor Oosterkamp BSc Pauline M. M. Theelen MSc Christianne A. R. Lok MD PhD Joanne A. de Hullu MD PhD Huberdina P. M. Smedts MD PhD M. Caroline Vos MD PhD Brenda M. Pijlman MD Loes F. S. Kooreman MD Johan Bulten MD PhD Marjolein H. F. M. Lentjes-Beer MD PhD Steven L. Bosch MD PhD Anja van de Stolpe MD PhD Sandrina Lambrechts MD PhD Ruud L. M. Bekkers MD PhD Jurgen M. J. Piek MD PhD 《Cancer》2023,129(9):1361-1371
Background
Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.Results
Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS. 相似文献2.
Steven P. Rowe MD PhD Martin G. Pomper MD PhD 《CA: a cancer journal for clinicians》2022,72(4):333-352
The authors define molecular imaging, according to the Society of Nuclear Medicine and Molecular Imaging, as the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems. Although practiced for many years clinically in nuclear medicine, expansion to other imaging modalities began roughly 25 years ago and has accelerated since. That acceleration derives from the continual appearance of new and highly relevant animal models of human disease, increasingly sensitive imaging devices, high-throughput methods to discover and optimize affinity agents to key cellular targets, new ways to manipulate genetic material, and expanded use of cloud computing. Greater interest by scientists in allied fields, such as chemistry, biomedical engineering, and immunology, as well as increased attention by the pharmaceutical industry, have likewise contributed to the boom in activity in recent years. Whereas researchers and clinicians have applied molecular imaging to a variety of physiologic processes and disease states, here, the authors focus on oncology, arguably where it has made its greatest impact. The main purpose of imaging in oncology is early detection to enable interception if not prevention of full-blown disease, such as the appearance of metastases. Because biochemical changes occur before changes in anatomy, molecular imaging—particularly when combined with liquid biopsy for screening purposes—promises especially early localization of disease for optimum management. Here, the authors introduce the ways and indications in which molecular imaging can be undertaken, the tools used and under development, and near-term challenges and opportunities in oncology. 相似文献
3.
4.
5.
6.
7.
Joshua Demb Esther K. Wei Monika Izano Stephen Kritchevsky Helen Swede Anne B. Newman Michael Shlipak Tomi Akinyemiju Steven Gregorich Dejana Braithwaite 《Journal of Geriatric Oncology》2019,10(2):265-271
Objectives
We examined the association between three inflammatory markers (Interleukin (IL)-6, C-reactive protein (CRP), tumor necrosis factor (TNF)-α) and incident lung cancer using baseline, updated, and averaged inflammatory measures in older adults.Methods
We fitted multivariable Cox models to assess whether circulating levels of inflammation markers were associated with incident lung cancers in the Health Aging, Body and Composition (HealthABC) prospective cohort of 3075 older adults aged 70–79?years at baseline. IL-6 and CRP were measured biennially, whereas TNF-α was measured at baseline.Results
Baseline levels of IL-6 were significantly associated with incident lung cancer risk in a model that adjusted for age, gender, race, and site (Model 1) (Hazard RatioT3 vs. T1: 3.34, 95% Confidence Interval: 1.91, 5.85) and in a model adjusted for health factors linked to chronic inflammation (Model 2) (HR T3 vs. T1: 2.57, 95% CI: 1.41, 4.65). The associations observed in time-updated IL-6 (HR T3 vs. T1: 2.47, 95% CI: 1.43, 4.28), cumulatively averaged IL-6 (HR T3 vs. T1: 2.47, 95% CI: 1.43, 4.35), and baseline CRP levels (HR T3 vs. T1: 1.85, 95% CI: 1.11, 3.08) with incident lung cancer in Model 1 were not statistically significant in Model 2.Conclusions
Baseline CRP and IL-6 levels were associated with increased risk of lung cancer in Model 1 and both models, respectively. Chronic IL-6 inflammation, as quantified by repeated measures was associated with incident lung cancer in Model 1, but not Model 2. Further research is needed to understand the role of CRP and IL-6 in lung carcinogenesis. 相似文献8.
9.